Transchem Ltd
- Market Cap ₹ 399 Cr.
- Current Price ₹ 326
- High / Low ₹ 378 / 46.0
- Stock P/E 59.4
- Book Value ₹ 68.3
- Dividend Yield 0.00 %
- ROCE 6.90 %
- ROE 5.29 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 4.78 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.98% over last 3 years.
- Earnings include an other income of Rs.12.7 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -0.20 | 0.00 | 0.34 | 2.63 | 0.00 | 0.00 | |
| 0.78 | 0.93 | 0.98 | 1.69 | 1.18 | 1.39 | 1.88 | 2.54 | 1.73 | 2.08 | 4.09 | 3.63 | 4.07 | |
| Operating Profit | -0.78 | -0.93 | -0.98 | -1.69 | -1.18 | -1.39 | -1.93 | -2.74 | -1.73 | -1.74 | -1.46 | -3.63 | -4.07 |
| OPM % | -511.76% | -55.51% | |||||||||||
| 2.09 | 1.97 | 1.78 | 2.11 | 2.75 | 2.76 | 26.82 | 6.66 | 4.24 | 7.40 | 8.53 | 9.25 | 12.74 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Depreciation | 1.07 | 1.02 | 1.02 | 0.97 | 0.80 | 0.57 | 0.12 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 |
| Profit before tax | 0.24 | 0.02 | -0.22 | -0.55 | 0.77 | 0.80 | 24.77 | 3.91 | 2.50 | 5.65 | 7.06 | 5.61 | 8.61 |
| Tax % | 45.83% | -150.00% | 0.00% | 116.36% | 61.04% | 47.50% | 2.50% | 26.60% | 50.80% | 25.66% | 26.06% | 23.53% | |
| 0.12 | 0.05 | -0.22 | -1.19 | 0.31 | 0.41 | 24.15 | 2.87 | 1.24 | 4.20 | 5.23 | 4.30 | 6.72 | |
| EPS in Rs | 0.10 | 0.04 | -0.18 | -0.97 | 0.25 | 0.33 | 19.73 | 2.34 | 1.01 | 3.43 | 4.27 | 3.51 | 5.49 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 56% |
| 5 Years: | 14% |
| 3 Years: | 58% |
| TTM: | 48% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 34% |
| 5 Years: | 69% |
| 3 Years: | 138% |
| 1 Year: | 567% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 | 12.24 |
| Reserves | 26.11 | 26.15 | 25.75 | 24.57 | 25.74 | 24.53 | 50.70 | 54.06 | 53.60 | 63.41 | 67.08 | 71.34 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.22 | 0.23 | 0.17 | 0.17 | 0.39 | 0.30 | 0.48 | 0.51 | 0.39 | 0.66 | 0.40 | 4.15 | |
| Total Liabilities | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
| 8.40 | 7.42 | 6.40 | 5.43 | 4.27 | 3.70 | 0.11 | 0.10 | 0.09 | 0.09 | 0.05 | 0.02 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 27.50 | 28.01 | 29.79 | 10.21 | 5.93 | 3.69 | 8.69 | 8.82 | 8.23 | 8.91 | 2.04 | 1.97 |
| 2.67 | 3.19 | 1.97 | 21.34 | 28.17 | 29.68 | 54.62 | 57.89 | 57.91 | 67.31 | 77.63 | 85.74 | |
| Total Assets | 38.57 | 38.62 | 38.16 | 36.98 | 38.37 | 37.07 | 63.42 | 66.81 | 66.23 | 76.31 | 79.72 | 87.73 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.94 | 1.08 | 0.55 | -19.79 | 10.34 | -0.63 | -27.72 | 21.91 | 1.22 | -39.31 | 36.00 | -2.89 | |
| -1.21 | -0.26 | -1.51 | 19.78 | 5.73 | 0.67 | 23.06 | 0.60 | -0.94 | 5.12 | 6.02 | 1.65 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | -0.27 | 0.83 | -0.95 | -0.01 | 16.07 | 0.04 | -4.66 | 22.51 | 0.28 | -34.18 | 42.02 | -1.24 |
| Free Cash Flow | 0.94 | 1.04 | 0.55 | -19.79 | 10.53 | -0.63 | -1.79 | 21.91 | 1.22 | -39.31 | 36.53 | -1.31 |
| CFO/OP | -121% | -116% | -56% | 1,165% | -897% | 0% | 1,401% | -853% | -132% | 2,182% | -2,618% | 47% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 440.15 | 376.10 | ||||||||
| Inventory Days | 35,770.00 | 32,485.00 | -511.00 | -273.75 | 0.00 | 0.00 | ||||||
| Days Payable | 0.00 | 0.00 | ||||||||||
| Cash Conversion Cycle | -511.00 | -273.75 | 440.15 | 376.10 | ||||||||
| Working Capital Days | 311,418.00 | 42,705.00 | 71,421.91 | 4,856.03 | ||||||||
| ROCE % | 0.63% | 0.05% | -0.58% | -1.47% | 1.63% | 2.03% | 4.61% | 4.22% | 3.50% | 7.99% | 9.11% | 6.90% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Investment Portfolio Value ₹ Lakhs |
|
|||||||||
| Loan Book (Loans to Body Corporates / Inter-Corporate Deposits outstanding) ₹ Lakhs |
||||||||||
| Number of Investment Holdings Count |
||||||||||
| Number of Permanent Employees Count |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
- Transchem acquired 100% of Greshma Shares and Stocks for ₹25.91 crore on August 17, 2026.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
- Transchem acquired 100% of Greshma Shares & Stocks for Rs 25.91 crore on August 17, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- Monitoring agency report for Q1 FY27 shows no deviation; preferential warrant proceeds remain unutilized in bank, FD, and liquid fund.
-
Amendment To The Code Of Conduct For Prevention Of Insider Trading
- Board approved amended insider trading code on August 10, 2026.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Exit from Mushroom manufacturing:[1]
The company previously operated a 100% Export Oriented Unit for mushroom cultivation and processing. The plant remained non-operational for several years following changes in the international horticulture market. Historical filings do not provide rated capacity, customer concentration or country-wise export contribution.
The entire mushroom undertaking—including land at Bebadohol and Urse villages in Maval, Pune, buildings, machinery and fixtures—was sold for ₹26 crore. The sale deed was registered on June 17, 2020, after which manufacturing, capacity and export metrics ceased to be applicable.[2][3]